Loading…
Traws Pharma, Inc. is projected to decline to $0.6438 by 2027, a -15% move from its current price of $0.76. TRAW is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $0.7158 | $0.7596 | $0.8061 | -0.05% |
| Jul 15 | $0.6981 | $0.7592 | $0.8258 | -0.10% |
| Jul 16 | $0.6847 | $0.7589 | $0.8411 | -0.15% |
| Jul 17 | $0.6735 | $0.7585 | $0.8541 | -0.20% |
| Jul 18 | $0.6638 | $0.7581 | $0.8658 | -0.25% |
| Jul 19 | $0.6551 | $0.7577 | $0.8764 | -0.30% |
| Jul 20 | $0.6472 | $0.7573 | $0.8862 | -0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6472 | $0.7573 | $0.8862 | -0.35% |
| Week 2 | $0.6043 | $0.7547 | $0.9425 | -0.70% |
| Week 3 | $0.5728 | $0.752 | $0.9873 | -1.05% |
| Week 4 | $0.5473 | $0.7494 | $1.03 | -1.39% |
| Week 5 | $0.5255 | $0.7468 | $1.06 | -1.74% |
| Week 6 | $0.5064 | $0.7442 | $1.09 | -2.08% |
| Week 7 | $0.4893 | $0.7416 | $1.12 | -2.43% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small synthetic molecules for respiratory viral diseases and cancer.
Headquartered in Newtown, Pennsylvania, the company was incorporated in 1998 and renamed from Onconova Therapeutics, Inc. to Traws Pharma, Inc. in April 2024.
The company is advancing investigational therapies such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza; narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies; and rigosertib, investigated in various cancers. It has license agreements with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University.
Traws Pharma, Inc. trades under the symbol TRAW. It sits in the Healthcare sector with a current price of $0.76 and a market capitalization of $11.57M, ranking 5101 by market size.
The near-term price outlook is mixed, with a neutral technical backdrop and limited upside relative to recent levels.
In the longer horizon, forecasts point to gradual upside, with notable gains projected into the 2030s and a substantial rise by 2050.
A major floor 84.2% below — a decisive break under it would weaken the trend.
The nearest floor, 13.2% below — buyers have tended to step in here.
The nearest ceiling, 100.0% above — a clean break opens room to run.
A major ceiling 192.1% above — clearing it would confirm fresh momentum.
Key TRAW support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TRAW market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.716 | Buy | $0.7294 | Buy |
| MA 10 | $0.765 | Sell | $0.7677 | Sell |
| MA 20 | $0.8435 | Sell | $0.8815 | Sell |
| MA 50 | $1.28 | Sell | $1.15 | Sell |
| MA 100 | $1.47 | Sell | $1.39 | Sell |
| MA 200 | $1.79 | Sell | $1.82 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.15 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -59.70 | Neutral |
| Williams %R (14) | -56.52 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -9.52 | Sell |
| Bollinger %B (20,2) | 0.37 | Neutral |
| Stochastic %K (14) | 43.48 | Neutral |
| TRIX (15) | -2.15 | Sell |
| Awesome (5,34) | -0.37 | Sell |
| Ultimate (7,14,28) | 36.40 | Neutral |
| Momentum (10) | -0.07 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 0.67 | Buy |
| ADX (14) | 31.97 | Sell |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is NEUTRAL. The RSI14 is 40, reflecting modest momentum. The stock trades below both the 50-day and 200-day moving averages, with SMA50 at $1.28 and SMA200 at $1.79.
Current support is at $0.66 and resistance at $1.52. The 30-day price range spans from $0.5138 to $1.12, signaling a narrow trading window and limited near-term upside.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.66 | $0.76 | $0.9073 | 0% | Neutral | |
| $0.4671 | $0.6438 | $0.9594 | -15% | Bearish | |
| $0.4394 | $0.6436 | $1.02 | -15% | Bearish | |
| $0.4081 | $0.6297 | $1.05 | -17% | Bearish | |
| $0.5138 | $0.8311 | $1.44 | +9% | Neutral | |
| $0.5439 | $0.9195 | $1.65 | +21% | Bullish | |
| $0.5334 | $0.9406 | $1.74 | +24% | Bullish | |
| $0.4874 | $0.895 | $1.70 | +18% | Neutral | |
| $0.3992 | $0.7625 | $1.49 | 0% | Neutral | |
| $0.3908 | $0.7759 | $1.55 | +2% | Neutral | |
| $0.5419 | $1.20 | $2.64 | +58% | Bullish | |
| $0.9726 | $2.16 | $4.97 | +184% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.66 | $0.76 | $0.9643 | +0.00% |
| August 2026 | $0.6443 | $0.7804 | $0.9844 | +2.69% |
| September 2026 | $0.591 | $0.726 | $0.935 | -6.97% |
| October 2026 | $0.5792 | $0.7202 | $0.9438 | -0.80% |
| November 2026 | $0.5797 | $0.7284 | $0.9683 | +1.13% |
| December 2026 | $0.5309 | $0.6736 | $0.9073 | -7.53% |
Click any year to see its month-by-month TRAW forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TRAW is projected to trade between $0.66 and $0.9073, averaging $0.76 — a potential gain of 0% from today's $0.76. A consolidation phase looks the most probable path here.
Traws Pharma, Inc.'s 2027 outlook centres on $0.6438, within a $0.4671 to $0.9594 range. That is -15% versus the projected 2026 average. That marks a -15% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2028, TRAW could reach as high as $1.02, with a base case around $0.6436 and support toward $0.4394 — roughly -15% from $0.76. Expect choppier, lower action through this leg of the cycle.
Expect TRAW to range from $0.4081 to $1.05 through 2029. The $0.6297 average target implies a -17% move from current prices. That is -2% versus the projected 2028 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The TRAW price prediction for 2030 points to an average of $0.8311 (low $0.5138, high $1.44) — a potential gain of +9% on today's $0.76. A consolidation phase looks the most probable path here.
In 2031, TRAW is projected to trade between $0.5439 and $1.65, averaging $0.9195 — a potential gain of +21% from today's $0.76. That is up +11% on the projected 2030 average. Momentum favours further upside here.
Traws Pharma, Inc.'s 2032 outlook centres on $0.9406, within a $0.5334 to $1.74 range. That is up +2% on the projected 2031 average. That marks a +24% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, TRAW could reach as high as $1.70, with a base case around $0.895 and support toward $0.4874 — roughly +18% from $0.76. Price action looks broadly range-bound.
Expect TRAW to range from $0.3992 to $1.49 through 2034. The $0.7625 average target implies a 0% move from current prices. That is -15% versus the projected 2033 average. A consolidation phase looks the most probable path here.
The TRAW price prediction for 2035 points to an average of $0.7759 (low $0.3908, high $1.55) — a potential gain of +2% on today's $0.76. Price action looks broadly range-bound.
In 2040, TRAW is projected to trade between $0.5419 and $2.64, averaging $1.20 — a potential gain of +58% from today's $0.76. That is up +55% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Traws Pharma, Inc.'s 2050 outlook centres on $2.16, within a $0.9726 to $4.97 range. That is up +79% on the projected 2040 average. That marks a +184% change versus current levels. Momentum favours further upside here.
Investing $1,000 in TRAW today (≈ 1,315.789474 TRAW) could be worth
$2,843.99
+$1,843.99 (+184%) by 2050 · US Dollar
Based on the average projected TRAW price of $2.16 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TRAWwould be worth at today's price.
$1,000 invested in TRAW on Jul 10, 2025 (≈ 636.942654 TRAW) would be worth
$484.08
-$515.92 (-51.6%) today · 0.48× · US Dollar
Based on a TRAW entry price of $1.57 vs. today's $0.76.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.77 | $987.01 | -1.3% |
| 1 month ago | $1.25 | $608 | -39.2% |
| 3 months ago | $1.48 | $513.51 | -48.6% |
| 6 months ago | $1.27 | $598.43 | -40.2% |
| 1 year ago | $1.57 | $484.08 | -51.6% |
| All time (5.0y) ago | $139 | $5.47 | -99.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TRAW forecast.
Our base-case forecast reaches $1.50 around 2050.
Implied market cap at $1.50: $22.84M
Forecasts show a multi-year path with a mix of near-term softness and longer-term upside. In 2026 the average forecast is $0.76 with a neutral stance. Bearish conditions are projected for 2027 and 2028 (avg $0.6438 and $0.6436, respectively) and 2029 (avg $0.6297), each with negative ROI around the high-teens.
By 2030 the average is $0.8311 with a 9.3% ROI and a neutral sentiment. The 2031 and 2032 forecasts are bullish, with averages of $0.9195 and $0.9406 and ROI of 21% and 23.8%, respectively. The 2033–2035 window remains neutral, while 2040 shows a strong bullish tilt with an average of $1.20 and a 58.5% ROI, and 2050 projects an average of $2.16 with a 184.4% ROI and a bullish sentiment.
Tap a question to reveal the answer.
The 2030 forecast is min $0.5138, avg $0.8311, max $1.44; ROI 9.3%; sentiment NEUTRAL.
Forecasts show a mix of neutral to bearish in the near term (2026–2029) and bullish later years, with notable ROI in 2031 (21%), 2032 (23.8%), 2040 (58.5%), and 2050 (184.4%). These are estimates, not guarantees.
Yes, the 2031 forecast includes a max of $1.65, with an average of $0.9195 and a 21% ROI; sentiment is BULLISH.
The 2040 forecast shows min $0.5419, avg $1.20, max $2.64 with a 58.5% ROI and a BULLISH sentiment.
Current price is $0.76 and market capitalization is $11.57M.
Traws Pharma, Inc. Community Discussion
0Share your Traws Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.